Target
ROS1
9 products, 9 indications
Indications
ROS1-rearranged NSCLC (3 products)
NSCLC (3 products)
ALK-rearrangement positive NSCLC (2 products)
NSCLC with EGFR exon 20 insertion mutations (1 products)
EGFR ex20ins-mutant NSCLC (1 products)
EGFRm+ NSCLC with CNS metastasis (1 products)
metastatic non-small cell lung cancer (1 products)
Stage III melanoma (1 products)
dedifferentiated liposarcoma (1 products)
Loading...
1 product
3 drugs
80 abstracts
Abstract
Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions.Org: Roche Products Ltd., Genentech, Memorial Sloan Kettering Cancer Center, Hopp Children’s Cancer Center Heidelberg (KiTZ), Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,
Abstract
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.Org: State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine,
Abstract
MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.Org: US Medical Affairs Oncology,
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.Org: Centrum für Integrierte Onkologie, Cancer Center Yonsei University College of Medicine,
Abstract
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).Org: Chang Gung Memorial Hospital Linkou Branch, Kuala Lumpur Hospital, Siriraj Hospital, Precision Medicine Asia, PREMIA Holdings (HK) Limited,
Abstract
A phase 1/2, open label study of amivantamab in combination with tyrosine kinase inhibitors among participants with advanced NSCLC harboring ALK, ROS1, and RET gene fusions.Org: University of Michigan - Rogel Cancer Center,
Abstract
Long-term survival of patients with lung cancer with kinase fusions (KF) treated at a tertiary community-based cancer program.Org: City of Hope - Atlanta,
Abstract
Immune infiltrate characterization and differential gene expression by RNA-sequencing analysis in patients with oncogene-addicted NSCLC with early progression under targeted therapy.Org: Genomic Platform and Biobank, AMMICa UAR3655/US23, Gustave Roussy, Cancer Campus,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
A real-world study on biomarker retesting among patients with non-small cell lung cancer and disparity in outcomes.Org: AbbVie Inc., North Chicago, IL, Perelman School of Medicine at the University of Pennsylvania, Abramson Cancer Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute,
Abstract
Evaluating progression-free survival of EGFR exon 20ins in patients with advanced non-small lung cancer receiving EGFR inhibitors: A real-world data study.Org: BioSpark AI Technologies,
Abstract
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.Org: Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Research Institute and Hospital, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Physical activity (PA) impact on metabolome and immunity of oncogene addicted non-small cell lung cancer (NSCLC): The EXcellenT trial.Org: Santa Maria delle Croci hospital Ravenna, AUSL della Romagna, Ravenna, UniSR, Servizio di Medicina dello Sport,
Abstract
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Netherlands Cancer Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).Org: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Seoul National University Hospital, Jongno-Gu, South Korea, Korea University Anam Hospital, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea,
Abstract
FAK inhibition with novel FAK/ALK inhibitor APG-2449 could overcome resistance in NSCLC patients who are resistant to second-generation ALK inhibitors.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Hunan Provincial Oncology Hospital, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC).Org: Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, RI-MUHC,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Impact on turnaround times (TAT) among non-squamous non-small cell lung cancer (NSCLC) patients across three time periods with varying biomarker testing techniques.Org: University of Toronto, Institute of Health Policy, Management, and Evaluation, University Health Network, Queen's University, Belfast, Princess Margaret Cancer Centre,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, The Sarah Cannon Research Institute, Division of Hematology/Oncology, Henry Ford Health System, Pfizer, Inc.,
Abstract
Relevance and accuracy of ChatGPT-generated NGS reports with treatment recommendations for oncogene-driven NSCLC.Org: University of Illinois Chicago, Department of Hematology Oncology, Kaiser Permanente, University of Illinois of Chicago College of Medicine, CancerIQ,
Abstract
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.Org: Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China, Fudan University Shanghai Cancer Center, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc.,
Abstract
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).Org: Illumina, Inc.,
Abstract
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.Org: NeoGenomics Ltd, Cambridge, United Kingdom, Medipole Lyon Villeurbanne, Villeurbanne, France, Infirmerie Protestante, Caluire Et Cuire, France, Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France,
Abstract
Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.Org: Gustave Roussy Cancer Campus, French National Authority for Health, Institut Curie, Saint Cloud, France, IHOPe-CLB, Paediatric Haematology-Oncology Department,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC).Org: Roche Products Ltd., F. Hoffmann-La Roche Ltd, Genentech, Inc., Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.Org: Mirati Therapeutics, Tempus Labs, Inc., Northwestern University-Feinberg School of Medicine,
Product
TMZAbstract
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Roche Products Ltd., F. Hoffmann-La Roche Ltd, Genentech, Centro de Investigación y Manejo del Cáncer (CIMCA),
Abstract
Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting.Org: EMD Serono Research & Development Institute, Genesis Research, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center,
Abstract
LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,
Abstract
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).Org: Foundation Medicine, Inc., Cambridge, MA, UC San Diego Moores Cancer Center,
Abstract
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Department of Molecular Pharmacology and Therapeutics,
Abstract
Ozone-loaded Pt(IV) prodrug self-assembled micelles with high bioavailability, low toxicity as a novel irradiation-controlled release treatment and the immune microenvironment editor for triple-negative breast cancer.Org: West China Hospital, Sichuan University, Chengdu, China, Breast Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China,
Abstract
Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users.Org: Siyemi Learning, ONCOassist, Department of Oncology, Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom,
Abstract
Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer.Org: Caris Life Sciences, Irving, TX, West Virginia University Health Sciences Center Department of Epidemiology and Biostatistics, Mayo Clinic, Penn State Milton S. Hershey Medical Center, Hershey, PA,
Abstract
Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Sendai Kousei Hospital,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
Receipt of financial drug assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer (NSCLC).Org: UCSF School of Medicine, University of California, San Francisco, Division of Endocrinology, San Francisco, CA,
Abstract
Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.Org: Integra Connect PrecisionQ, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists and Research Institute, Ocala, FL, Thermo Fisher Scientific,
Abstract
Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer.Org: Fortis Cancer Institute, Rajiv Gandhi Cancer Institute and Research Centre, Tata Memorial Centre, Datar Cancer Genetics, Datar Genetics Limited,
Abstract
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,
Abstract
Precision medicine applied to rare malignancies: A single-center experience at University Hospital of Verona.Org: Medical Oncology Group, Azienda Ospedaliera Universitaria Integrata di Verona, Investigational Cancer Therapeutics Clinical Unit and Section of Oncology, ARC-Net Research Centre - Diagnostic and Public Health Department, University of Verona - Faculty of Medicine,
Abstract
Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,
Abstract
Influence of follow-up time on outcome of children and adolescents with atypical Spitz tumor/Spitz melanoma (AST/SM): Results from the MACMEL registry.Org: St Jude Childrens Research Hospital, St. Jude Children's Research Hospital, Department of Oncology, St. Jude Children's Research Hospital,
Abstract
Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients.Org: Biofidelity Ltd,
Abstract
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.Org: Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Guangzhou JOYO Pharma,
Abstract
Reality check for precision oncology in squamous cell lung cancer.Org: UAMS-Winthrop Rockefeller Cancer Institute, UAMS Medical College Physicians Group,
Abstract
Gaps and factors in patient awareness of biomarker test timing and purpose in non-small cell lung cancer (NSCLC): Baseline assessment for implementation of 4R Oncology model.Org: Department of Medicine, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Center for Business Models on Healthcare, Glencoe, IL, Johns Hopkins Hospital, Baltimore, MD, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, Emory University Hospital, Atlanta, GA, Emory University, Atlanta, GA, Grady Memorial Hospital, Atlanta, GA, SOMC Cancer Center, Portsmouth, OH, SOUTHERN OHIO MEDICAL CENTER, Portsmouth, OH, Southern Ohio Medical Center, Portsmouth, OH, Northwestern Memorial Hospital, Chicago, IL, Northwestern University, Chicago, IL, Wake Forest School of Medicine, Winston-Salem, NC, LUNGevity Foundation, Bethesda, MD, Association of Community Cancer Centers, Rockville, MD, Association of Community Cancer Centers (ACCC), Rockville, MD, Center for Business Models in Healthcare, Glencoe, IL,
Abstract
Anaplastic lymphoma kinase (ALK) and ROS 1– positive advanced NSCLC: A real-world institutional experience.Org: NIMS - Nizam's Institute of Medical Sciences, NIMH - National Institute of Mental Health, Nimble Science, Amazon, Google Cloud, Munich, Germany,
Abstract
Oncomine Dx Express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation.Org: Thermo Fisher Scientific, Austin Health, Txinno Bioscience,
Abstract
Examining molecular testing practices and targeted therapy use in advanced/metastatic non-small cell lung cancer (mNSCLC): A quality improvement initiative across ten community cancer centers.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, PRIME Education LLC,
Abstract
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).Org: University of Chicago, Janssen Scientific Affairs, Analysis Group, Inc.,
Abstract
Delivery of precision oncology in advanced lung cancer: Gaps, barriers, and potential solutions.Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Chapel Hill, NC, NC Translational and Clinical Sciences Institute, The University of North Carolina at Chapel Hill, University of North Carolina School of Public Health,
Abstract
Treatment of newly developed metastases after definitive chemoradiotherapy +/- ICI for unresectable stage III NSCLC.Org: Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, Munich, Bavaria, Germany, Ludwig-Maximilians-University of Munich and Thoracic Oncology Centre, Munich, Germany, Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting, Germany, Thoracic Oncology, Asklepios Clinics Munich-Gauting, Germany, Gauting, Germany,
Abstract
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.Org: US Oncology Research/New York Oncology Hematology, Albany, NY, US Oncology Research/Oncology Associates of Oregon P.C., Eugene, OR, US Oncology Research/Virginia Oncology Associates, Newport News, VA, US Oncology Research/Oncology Hematology Care, Inc., The Woodlands, TX, US Oncology Research/Virginia Cancer Specialists, Fairfax, VA,
Abstract
Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma.Org: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Pekin, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College., Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Caner Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Department of diagnostic radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Genecast Biotechnology Co., Ltd., Wuxi, China,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting.Org: EMD Serono Research & Development Institute, Rockland, MA, Genesis Research, Hoboken, NJ, Memorial Sloan Kettering Cancer Center,
Abstract
Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.Org: Delfi Diagnostics, Inc., DELFI Diagnostics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
High-throughput drug screening (HTDS) of patient-derived tumor organoids (PTDO) from advanced gastrointestinal malignancies: Response and identification of novel therapeutic options.Org: Weill Cornell Medical College University, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, NewYork-Presbyterian/Weill Cornell Medical Center, Joan and Sanford I Weill Medical College of Cornell University, NYP/Columbia,
Abstract
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.Org: Cancer Center Zhejiang University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,
Abstract
Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.Org: Fortis Cancer Institute, New Delhi, India, Fortis Cancer Institute, Bangalore Karnataka, India, Fortis Cancer Institute, Gurgaon, Haryana, India, Fortis Cancer Institute, Delhi, India, Fortis Hospital and research centre, New Delhi, India,
Abstract
Artificial intelligence (AI) –powered H&E whole-slide image (WSI) analysis of tertiary lymphoid structure (TLS) correlates with immune phenotype and related molecular signatures in non–small-cell lung cancer.Org: Oncology Therapeutic Development, Lunit Inc., Northwestern University Feinberg School of Medicine,
Abstract
Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC).Org: Cerba Research, Montpellier Cancer Institute, France, Montreal, QC Kinetix,
Abstract
Impact of a pathologist-driven molecular testing protocol on veterans with non-small cell lung cancer.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, University of California Irvine, Los Angeles Medical Center, West Los Angeles VA Health Care System, University of California Los Angeles Medical Center/Veterans Affairs,
Abstract
Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: A comparative study.Org: Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Asst Prof Johns Hopkins University, US, Asst Prof Lee Kong Chian/NTU, Singapore, Singapore, Tan Tock Seng Hospital-National Healthcare Group, Singapore, Singapore, Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Singapore, Tan Tock Seng Hospital, Singapore, Singapore, Clinical Research&Innovation Office, TTSH, Singapore, Singapore, Tan Tock Seng Hospital-National Healthcare Group (Singapore), Singapore, Singapore, Tan Tock Seng Hospital-(Singapore), Singapore, Singapore, Lucence Health, Palo Alto, Lucence Health, Singapore, Singapore,
Abstract
Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.Org: Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, NY, India, Adana Acıbadem Hospital, Adana, Turkey, St Bartholomew's Hospital, London, United Kingdom, Fortis Cancer Institute, New Delhi, India, Imperial College London, London, United Kingdom,
Abstract
Biomarker testing and treatment patterns in US patients (pts) with advanced/metastatic non‑small cell lung cancer (NSCLC) harboring MET amplification.Org: West Cancer Center & Research Institute, Merck, ConcertAI,
Abstract
Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).Org: Merck & Co, Inc., Merck & Co., Inc., Merck and Co, Inc.,
Abstract
Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.Org: OneCell Dx, Tata Memorial Hospital (HBNI), OneCell Diagnostics, School of Consciousness, MIT WPU, Indx Technology,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,
Abstract
High-confidence AI-based biomarker profiling for H&E slides to optimize pathology workflow in lung cancer.Org: Imagene AI LTD, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Tel Aviv Sourasky Medical center, Tel Aviv, Israel, Institute of Oncology Angel H Roffo,
Drug
taletrectinibAbstract
Genomic characterization of papillary thyroid carcinoma in Chinese Shandong population.Org: Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Jinan, China, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Department of Thyroid and Breast, The 960th hospital of PLA, Jinan, China, Department of External Medicine, Jinan Huaiyin People's Hospital, Jinan, China, Second Department of Breast Diseases/Second Department of Thyroid Diseases, The Second People's Hospital of Shandong Province, Jinan, China,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Drug
brigatinib